Cell therapy (Stem-cell derived) · Cell replacement: spinal cord tissue · developed by Lineage Cell Therapeutics
AST-OPC1 is a cell therapy consisting of oligodendrocyte progenitor cells derived from embryonic stem cells. It is administered by direct injection into damaged spinal cord tissue and is being studied in acute and chronic spinal cord injury.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02302157 | Phase 1/2 | Cervical Spinal Cord Injury | Completed | LCTX |
| NCT06841770 | Phase 1 | Spinal Cord Injury Cervical | Recruiting | LCTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Spinal Cord InjurySpinal Cord Injury CervicalSpinal Cord Injury ThoracicSpinal Cord Injury, AcuteSpinal Cord Injury, ChronicCervical Spinal Cord InjurySpinal Cord TraumaSpine Injury
Updated Oct 3, 2026. Something wrong or missing? Report it on the LCTX page.
See LCTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LCTX catalysts and pipeline →